Beneficial effect of adjuvant dabrafenib plus trametinib on recurrence-free survival in patients with resected BRAFV600-mutant stage III melanoma seems to be short-lived

Kenneth R. Hess

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Beneficial effect of adjuvant dabrafenib plus trametinib on recurrence-free survival in patients with resected BRAFV600-mutant stage III melanoma seems to be short-lived'. Together they form a unique fingerprint.